BRIEF—Pharmanovia in-licenses AGHD diagnosis drug

UK-based Pharmanovia has expanded its endocrinology portfolio with a licensing agreement for Ghryvelin (macimorelin), a new medicine used for diagnosing adult growth hormone deficiency (AGHD) from US biopharma Aeterna Zentaris.

The agreement gives Pharmanovia the exclusive commercial rights in the UK and European Economic Area.

Pharmanovia chief executive, James Burt said: ‘’Endocrinology is the largest of our four core therapy areas and the in-licensing of this important novel medicine, the second in-licensing deal of a novel medicine in almost as many weeks, speaks to our ability to in-license novel, complementary products in the therapeutic settings we support.”